CA3121918A1 - Methods for treating cancer in models harboring esr1 mutations - Google Patents

Methods for treating cancer in models harboring esr1 mutations Download PDF

Info

Publication number
CA3121918A1
CA3121918A1 CA3121918A CA3121918A CA3121918A1 CA 3121918 A1 CA3121918 A1 CA 3121918A1 CA 3121918 A CA3121918 A CA 3121918A CA 3121918 A CA3121918 A CA 3121918A CA 3121918 A1 CA3121918 A1 CA 3121918A1
Authority
CA
Canada
Prior art keywords
elacestrant
subject
cancer
estrogen receptor
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3121918A
Other languages
English (en)
French (fr)
Inventor
Hitisha PATEL
Teeru BIHANI
Heike ARLT
Nianjun Tao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Radius Pharmaceuticals Inc
Original Assignee
Radius Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radius Pharmaceuticals Inc filed Critical Radius Pharmaceuticals Inc
Publication of CA3121918A1 publication Critical patent/CA3121918A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3121918A 2018-12-06 2019-12-06 Methods for treating cancer in models harboring esr1 mutations Pending CA3121918A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862776338P 2018-12-06 2018-12-06
US62/776,338 2018-12-06
PCT/US2019/064980 WO2020118202A1 (en) 2018-12-06 2019-12-06 Methods for treating cancer in models harboring esr1 mutations

Publications (1)

Publication Number Publication Date
CA3121918A1 true CA3121918A1 (en) 2020-06-11

Family

ID=69158304

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3121918A Pending CA3121918A1 (en) 2018-12-06 2019-12-06 Methods for treating cancer in models harboring esr1 mutations

Country Status (14)

Country Link
US (1) US20220016052A1 (ru)
EP (1) EP3890835A1 (ru)
JP (2) JP7497353B2 (ru)
KR (1) KR20210100135A (ru)
AU (1) AU2019392908A1 (ru)
BR (1) BR112021010141A2 (ru)
CA (1) CA3121918A1 (ru)
EA (1) EA202191256A1 (ru)
IL (1) IL283655A (ru)
JO (1) JOP20210138A1 (ru)
MA (1) MA54393A (ru)
MX (1) MX2021006412A (ru)
SG (1) SG11202105915UA (ru)
WO (1) WO2020118202A1 (ru)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2737496C2 (ru) 2015-04-29 2020-12-01 Радиус Фармасьютикалз, Инк. Способы лечения рака

Also Published As

Publication number Publication date
SG11202105915UA (en) 2021-07-29
BR112021010141A2 (pt) 2021-08-24
KR20210100135A (ko) 2021-08-13
US20220016052A1 (en) 2022-01-20
WO2020118202A1 (en) 2020-06-11
MA54393A (fr) 2021-10-13
EA202191256A1 (ru) 2021-10-06
JP2024101017A (ja) 2024-07-26
JOP20210138A1 (ar) 2023-01-30
JP7497353B2 (ja) 2024-06-10
EP3890835A1 (en) 2021-10-13
JP2022511497A (ja) 2022-01-31
AU2019392908A1 (en) 2021-06-10
IL283655A (en) 2021-07-29
MX2021006412A (es) 2021-07-21

Similar Documents

Publication Publication Date Title
US11413258B2 (en) Methods for treating cancer
US20210330612A1 (en) Methods for treating cancer resistant to cdk4/6 inhibitors
WO2020112765A1 (en) Elacestrant in combination with abemaciclib in women with breast cancer
US20220016052A1 (en) Methods for treating cancer in models harboring esr1 mutations
RU2822195C2 (ru) Способы лечения рака на моделях, имеющих мутации esr1
EA046925B1 (ru) Способы лечения рака на моделях, имеющих мутации esr1
EA047283B1 (ru) Способы лечения устойчивого к ингибиторам cdk4/6 рака